Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Posted by Don Miller on Sep 29th, 2026

Ainos, Inc. (NASDAQ:AIMD – Get Free Report) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totaling 55,787 shares, an increase of 172.6% from the August 31st total of 20,463 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 33,974 shares, the days-to-cover ratio is currently 1.6 days.

Ainos Trading Down 0.7%

Shares of NASDAQ AIMD opened at $1.33 on Tuesday. The stock has a market cap of $9.82 million, a price-to-earnings ratio of -0.53 and a beta of 2.47. Ainos has a 1-year low of $1.25 and a 1-year high of $4.44. The stock’s 50-day moving average is $1.44 and its 200 day moving average is $1.66.

Ainos (NASDAQ:AIMD – Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($0.62) earnings per share (EPS) for the quarter. Ainos had a negative return on equity of 217.50% and a negative net margin of 11,912.10%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Ainos presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on AIMD

Ainos Company Profile

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a healthcare technology company developing solutions in artificial intelligence, point-of-care testing and telehealth. The company focuses on technologies intended to support non-invasive disease screening, decentralized healthcare delivery and improved access to diagnostic services.

Ainos’ AI Nose platform uses artificial intelligence and analysis of volatile organic compounds to identify patterns that may be associated with certain health conditions. The company is also developing point-of-care testing products and related diagnostic applications designed for use outside traditional laboratory settings.

In addition, Ainos has worked on telehealth solutions and therapeutic products, including its VELDONA low-dose interferon-alpha platform.